Agence France-Presse: Malaria vaccine gets go-ahead from European regulators
“European regulators on Friday gave the go-ahead for the world’s most advanced malaria candidate vaccine, despite mixed results from a years-long trial on nearly 15,500 children in seven African countries…” (7/24).

Financial Times: World’s first malaria vaccine gets green light from Europe
“…GSK, the U.K.’s biggest drugmaker, announced on Friday that it had received a ‘positive scientific opinion’ from the European Medicines Agency for its Mosquirix vaccine…” (Ward, 7/24).

The Guardian: First malaria vaccine given green light by European regulators
“…The shot has been developed by U.K. drugmaker GlaxoSmithKline and partly funded by the Bill & Melinda Gates Foundation. It has taken 30 years to develop it, at a cost of more than $565m (£364m) to date…” (Kollewe, 7/24).

Quartz: A malaria vaccine nearly 30 years in the making just got a green light from E.U. regulators
“…[The vaccine] won the scientific approval of the European Medicines Agency, which was needed before the World Health Organization would consider supporting its use. A decision from the WHO is due in November. If it also gives the go-ahead, that would spur African nations to also approve the vaccine, which is not being considered for use in Europe…” (Mollman, 7/24).

Reuters: World’s first malaria vaccine gets regulatory go-ahead, faces WHO review
“…[The WHO] said on Friday it would begin a review in October on when and where [the vaccine] could be used. The [agency] aims to make a recommendation by November…” (Kelland et al., 7/24).

TIME: The First-Ever Malaria Vaccine Just Got a Big Break
“…Because the vaccine is not intended for countries outside of Africa, the European regulatory agency is not ‘approving’ the vaccine, but offering a positive opinion that the World Health Organization (WHO) will use to create its own recommendation for the vaccine’s use. Countries in Africa will then approve the vaccine through their own regulatory agencies…” (Sifferlin, 7/24).

Wall Street Journal: GlaxoSmithKline’s Malaria Vaccine Clears Final Scientific Hurdle
“…Once the WHO has made a policy decision, which could take several months, GAVI will consider its strategy for the vaccine. While GAVI has not yet explicitly committed to funding the jab, it is widely expected to do so…” (Roland, 7/24).